Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • FDA clears radioactive...

    FDA clears radioactive drug for digestive tract cancer that killed Steve Jobs

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2018-01-27T10:36:02+05:30  |  Updated On 27 Jan 2018 10:36 AM IST
    FDA clears radioactive drug for digestive tract cancer that killed Steve Jobs

    The U.S. Food and Drug Administration approved a radioactive drug to treat the ultra-rare type of digestive tract cancer that killed Steve Jobs in 2011.


    The approval for Advanced Accelerator Applications SA's Lutathera comes just days after Swiss giant Novartis AG closed its $3.9 billion acquisition of the French company.


    Lutathera is unusual in that it harnesses the same molecule that is used to diagnose cancer to also deliver the treatment.


    The radiopharmaceutical injection works by hitting cancer cells with high energy electrons, just like radiotherapy, but targets gastroenteropancreatic neuroendocrine tumours (GEP-NETs) that over-express a certain protein.


    Advanced Accelerator said Lutathera's list price is about $47,500 per dose, with the usual treatment period including four doses. This price is not necessarily what patients actually pay, as out-of-pocket costs vary based on a patient's insurance plan and rebates offered by drugmakers.


    The treatment reduced the risk of the disease progressing by 79 percent in a late-stage clinical trial, on the basis of which it was approved, Accelerator Applications said.


    In general, patients with well-and-moderately differentiated tumors, compared with healthy cells, have a roughly 35 percent probability of surviving for five years, the company estimates.


    This is the first U.S. approval for this kind of treatment, known as peptide receptor radionuclide therapy. The European Medicines Agency approved Lutathera in September and Novartis offered to buy Advanced Accelerator a month later.


    The FDA estimates that each year, one out of 27,000 people are diagnosed with GEP-NETs, a disease that killed Apple co-founder Jobs in 2011.


    It has been a long journey for Lutathera. The FDA rejected the drug in 2016, asking for more study data. The company resubmitted its marketing application in July last year.


    (Reporting by Manas Mishra in Bengaluru; Editing by Sai Sachin Ravikumar and Savio D'Souza)
    cancercancer cellsdigestive tract cancerDrugmakersgastroenteropancreatic neuroendocrine tumoursLutatheraNovartisradioactive drugradionuclideradiopharmaceutical injectiontumoursU.S. Food and Drug Administration
    Source : REUTERS

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok